Drug intelligence / Profile preview

NouvNeu002

Development stage: Preclinical
Lead developer: iRegene Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

NouvNeu002 is an induced pluripotent stem cell (iPSC)-derived cell therapy being developed by iRegene Therapeutics for the treatment of ischemic stroke. The therapy is designed to repair or replace neural tissue damaged during an ischemic event by delivering specialized cells derived from iPSCs. As of early 2024, the program is in the IND-enabling phase, with the company targeting Investigational New Drug (IND) submissions in both China and the United States during the second half of 2026.

Beyond the preview

Go deeper on NouvNeu002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NouvNeu002.

Explore the full profile